TG Therapeutics (NASDAQ:TGTX) Upgraded at StockNews.com

StockNews.com upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a sell rating to a hold rating in a report released on Tuesday morning.

TGTX has been the subject of several other reports. JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday. Finally, The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Stock Up 0.2 %

TGTX stock opened at $35.19 on Tuesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market capitalization of $5.48 billion, a P/E ratio of -351.86 and a beta of 2.30. TG Therapeutics has a 52-week low of $12.93 and a 52-week high of $37.58. The company’s 50 day simple moving average is $30.92 and its 200-day simple moving average is $28.38.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. As a group, equities research analysts anticipate that TG Therapeutics will post 0.08 EPS for the current year.

Insider Activity

In related news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.50% of the stock is owned by corporate insiders.

Institutional Trading of TG Therapeutics

Large investors have recently added to or reduced their stakes in the business. State Street Corp raised its holdings in shares of TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after purchasing an additional 2,398,015 shares in the last quarter. Clearbridge Investments LLC bought a new position in TG Therapeutics during the fourth quarter valued at about $55,237,000. Principal Financial Group Inc. lifted its position in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after buying an additional 725,371 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of TG Therapeutics during the 4th quarter worth about $14,508,000. Finally, Braun Stacey Associates Inc. acquired a new position in shares of TG Therapeutics during the 4th quarter valued at about $13,328,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.